title: Epidermal growth factor receptor (EGFR) signaling requires a specific endoplasmic reticulum thioredoxin for the post-translational control of receptor presentation to the cell surface.
abstract: The epidermal growth factor receptor (EGFR) is a well characterized receptor-tyrosine kinase that functions in development and serves a vital role in many human cancers. Understanding EGFR regulatory mechanisms, and hence approaches for clinical intervention, has focused on ligand-receptor interactions and tyrosine kinase activity. Here, we show using the NCI-H460 lung and A431 epidermoid human cancer cell lines that EGFR binding to anterior gradient homolog 2 (AGR2) in the endoplasmic reticulum is required for receptor delivery to the plasma membrane and thus EGFR signaling. Reduced AGR2 protein levels or mutation of an essential cysteine in the active site result in decreased cell surface EGFR and a concomitant decrease in signaling as reflected by AREG, EGR1, and FOS expression. Similar to previously described EGFR nulls, an AGR2 null also resulted in embryonic lethality. Consistent with its role in regulating EGFR-mediated signaling, AGR2 expression is also enhanced in many human cancers and promotes the transformed phenotype. Furthermore, EGFR-mediated signaling in NCI-H460 cells, which are resistant to the tyrosine kinase inhibitor AG1478, is also disrupted with reduced AGR2 expression. The results provide insights into why cancer prognosis or response to therapy often does not correlate with EGFR protein or RNA levels because they do not reflect delivery to the cell surface where signaling is initiated. AGR2, therefore, represents a novel post-translational regulator of EGFR-mediated signaling and a promising target for treating human cancers.
authors: From the Department of Medicine, Stanford University, Stanford, California 94305.
authors: Aiwen
authors: A
authors: Dong
authors: From the Department of Medicine, Stanford University, Stanford, California 94305.
authors: Dariusz
authors: D
authors: Wodziak
authors: From the Department of Medicine, Stanford University, Stanford, California 94305 lowe@stanford.edu.
authors: Anson W
authors: AW
authors: Lowe
mesh_terms: D000818:Animals; D016466:CHO Cells; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism*; D006224:Cricetinae; D003412:Cricetulus; D003553:Cystine / Q000378:metabolism; D004721:Endoplasmic Reticulum / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009088:Mucoproteins; D015513:Oncogene Proteins; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D021381:Protein Transport; D011506:Proteins / Q000378:metabolism*; D011799:Quinazolines / Q000494:pharmacology; D015398:Signal Transduction; D013879:Thioredoxins / Q000378:metabolism*; D020032:Tyrphostins / Q000494:pharmacology
chemical_list: C502296:AGR2 protein, human; D009088:Mucoproteins; D015513:Oncogene Proteins; D047428:Protein Kinase Inhibitors; D011506:Proteins; D011799:Quinazolines; D020032:Tyrphostins; C101044:RTKI cpd; D003553:Cystine; D013879:Thioredoxins; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: Cancer Biology; Cell Signaling; Endoplasmic Reticulum (ER); Epidermal Growth Factor Receptor (EGFR); Signal Transduction; Thioredoxin